![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, November 15, 2017 11:42:24 AM
Alternative Names: Ig-NP; IgP therapeutic; MCT-475; MCT-485
Latest Information Update: 04 Nov 2017
At a glance
Originator MultiCell Technologies Inc
Developer MultiCell Technologies Inc; University Health Network
Class Immunoglobulin fusion proteins; Recombinant fusion proteins; RNA
Mechanism of Action Apoptosis stimulants; Immunomodulators; Immunostimulants; T lymphocyte stimulants; Toll-like receptor 3 agonists; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists; Toll-like receptor agonists; Tumour necrosis factor alpha stimulants
Orphan Drug Status No
New Molecular Entity Yes
Highest Development Phases
Preclinical Viral hepatitis
No development reported Cancer; Hepatocellular carcinoma
http://adisinsight.springer.com/drugs/800025804
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM